Raf dimer inhibitors bind RAF heterodimers

Stable Identifier
R-HSA-9653108
Type
Reaction [binding]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

LY3009120, TAK-580 and TAK-632 are pan-RAF inhibitors that binds to all 3 RAF isoforms as well as to RAF dimers to inhibit phosphorylation of MAP2K and MAPK proteins (Nakamura et al, 2013; Okaniwa et al, 2013; Sun et al, 2017; Peng et al, 2015; Henry et al, 2015; Vakana et al, 2017). Because they inhibit the kinase activity of RAF homo- and heterodimers, treatment with pan-RAF dimer inhibitors generates minimal paradoxical RAF activation and inhibits cellular proliferation in a number of tumor models (Peng et al, 2015; Henry et al, 2015, Vakana et al, 2017; reviewed in Karoulia et al, 2017; Agianian and Gavathiotis, 2018; ).

Literature References
PubMed ID Title Journal Year
28082416 A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas

Sun, Y, Alberta, JA, Pilarz, C, Calligaris, D, Chadwick, EJ, Ramkissoon, SH, Ramkissoon, LA, Garcia, VM, Mazzola, E, Goumnerova, L, Kane, M, Yao, Z, Kieran, MW, Ligon, KL, Hahn, WC, Garraway, LA, Rosen, N, Gray, NS, Agar, NY, Buhrlage, SJ, Segal, RA, Stiles, CD

Neuro-oncology 2017
23906342 Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives

Okaniwa, M, Hirose, M, Arita, T, Yabuki, M, Nakamura, A, Takagi, T, Kawamoto, T, Uchiyama, N, Sumita, A, Tsutsumi, S, Tottori, T, Inui, Y, Sang, BC, Yano, J, Aertgeerts, K, Yoshida, S, Ishikawa, T

J. Med. Chem. 2013
28984291 New perspectives for targeting RAF kinase in human cancer

Karoulia, Z, Gavathiotis, E, Poulikakos, PI

Nat. Rev. Cancer 2017
27999210 LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer

Vakana, E, Pratt, S, Blosser, W, Dowless, M, Simpson, N, Yuan, XJ, Jaken, S, Manro, J, Stephens, J, Zhang, Y, Huber, L, Peng, SB, Stancato, LF

Oncotarget 2017
29461827 Current Insights of BRAF Inhibitors in Cancer

Agianian, B, Gavathiotis, E

J. Med. Chem. 2018
24121489 Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma

Nakamura, A, Arita, T, Tsuchiya, S, Donelan, J, Chouitar, J, Carideo, E, Galvin, K, Okaniwa, M, Ishikawa, T, Yoshida, S

Cancer Res. 2013
25965804 Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells

Henry, JR, Kaufman, MD, Peng, SB, Ahn, YM, Caldwell, TM, Vogeti, L, Telikepalli, H, Lu, WP, Hood, MM, Rutkoski, TJ, Smith, BD, Vogeti, S, Miller, D, Wise, SC, Chun, L, Zhang, X, Zhang, Y, Kays, L, Hipskind, PA, Wrobleski, AD, Lobb, KL, Clay, JM, Cohen, JD, Walgren, JL, McCann, D, Patel, P, Clawson, DK, Guo, S, Manglicmot, D, Groshong, C, Logan, C, Starling, JJ, Flynn, DL

J. Med. Chem. 2015
26343583 Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

Peng, SB, Henry, JR, Kaufman, MD, Lu, WP, Smith, BD, Vogeti, S, Rutkoski, TJ, Wise, S, Chun, L, Zhang, Y, Van Horn, RD, Yin, T, Zhang, X, Yadav, V, Chen, SH, Gong, X, Ma, X, Webster, Y, Buchanan, S, Mochalkin, I, Huber, L, Kays, L, Donoho, GP, Walgren, J, McCann, D, Patel, P, Conti, I, Plowman, GD, Starling, JJ, Flynn, DL

Cancer Cell 2015
Participants
Participant Of
hasEvent
Orthologous Events
Authored
Reviewed
Created
Cite Us!